Form 4 for SUPN SUPERNUS PHARMACEUTICALS, INC.
Accepted 2026-02-23 00:00:00 ET · period of report 2026-02-19 · accession 0001899935-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-02-23 | 2026-02-19 | SUPN | Sensenig Bethany | Dir | S - Sale+OE | $51.01 | -4,475 | 0 | -100% | -$228.3K |
| D | 2026-02-23 | 2026-02-19 | SUPN | Sensenig Bethany | Dir | M - OptEx | $0.00 | +4,475 | 4,475 | New | $0 |
| D | 2026-02-23 | 2026-02-19 | SUPN | Sensenig Bethany | Dir | M - OptEx | $0.00 | -4,475 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-19 | S | D | 1,217 | $50.31 | 3,258 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.83 to $50.71. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 2 | Common | Common Stock | 2026-02-19 | S | D | 3,258 | $51.27 | 0 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.98 to $51.56. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| 3 | Common | Common Stock | 2026-02-19 | M | A | 4,475 | $0.00 | 4,475 | D | — | — | |
| 4 | Derivative | Restricted Stock Unit | 2026-02-19 | M | D | 4,475 | $0.00 | 0 | D | — · — to — | 4,475 Common Stock | (F4) Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. (F5) These restricted stock units were settled in common stock upon vesting, which occurred on February 19, 2026. |